Study of Azer-cel for B-cell Mediated Autoimmune Disorders
This study is looking at a treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders, including certain types of multiple sclerosis (MS). The main goal is to find the safest and most effective dose of azer-cel. You might be able to join if you are between 18 and 60 years old and have been diagnosed with primary progressive MS, secondary progressive MS, or relapsing MS. The researchers will be watching closely for any side effects or safety concerns during the first 28 days after treatment. This study plans to enroll 100 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It aims to determine the recommended dose of azer-cel for future studies.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measures safety for 28 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
At a glance
Conditions
Where it's being run
8 sites across 6 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Number of Participants with Dose-Limiting Toxicities (DLTs)From Day 0 to Day 28
DLT will be determined using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.